Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever

Favipiravir (T-705) is a new anti-influenza drug approved for human use in Japan and progressing through Phase 3 clinical trials in the U.S. In addition to its potent inhibitory effects against influenza virus infection, the compound has been shown to be broadly active against RNA viruses from 9 dif...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antiviral Res
Hlavní autoři: Gowen, Brian B., Sefing, Eric J., Westover, Jonna B., Smee, Donald F., Hagloch, Joseph, Furuta, Yousuke, Hall, Jeffery O.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4536130/
https://ncbi.nlm.nih.gov/pubmed/26186980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2015.07.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky